Value of plasma free DNA in the diagnosis of non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-6902.2017.06.011

Abstract

Abstract:

Objective

To evaluate the value of plasma free DNA in the diagnosis of non-small cell lung cancer (NSCLC).

Methods

Plasma was collected from 116 patients with non-small cell lung cancer admitted to respiratory department, and 120 healthy subjects from Medical examination center, Shanxi Provincial People′s Hospital. Plasma free DNA was extracted and detected by fluorescence quantitative polymerase chain reaction, PCR.

Results

The plasma free DNA level of healthy people was (18.65±6.30) ng/ml, and the plasma free DNA level in patients with non-small cell lung cancer was (200.70±88.54) ng/ml, the difference was statistically significant(P<0.01). The plasma free DNA content of stage Ⅰ/Ⅱ non-small cell lung cancer was (172.75±72.87) ng/ml, and the plasma circulating DNA content in stage Ⅲ/Ⅳ non-small cell lung cancer was (221.88±93.86) ng/ml, (P<0.05). There was no significant correlation between sex, age, smoking status and histological type (P>0.05).

Conclusion

Plasma circulating DNA is a potentially valuable biomarker that may be an effective tool for early diagnosis and clinical staging of non-small cell lung cancer.

Key words: Non-small cell lung cancer, Plasma free DNA, Early diagnosis, Tumor marker

Jie Du, Yongjie Sui, Hongyan Li, Shuili Wang. Value of plasma free DNA in the diagnosis of non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(06): 686-689.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.06.011

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I06/686

Figures/Tables 2

References 20

1	钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]．中华肺部疾病杂志(电子版), 2011, 4(1):1-6.
2	Maione P, Rossi A, Sacco PC, et al. Advance in chemotherapy in advanced non-small-cell Lung cancer[J]. Expert Opin Pharmacother, 2010, 11(18):2997-3007.
3	Diaz LA Jr, Bardelli A. Liquid Biopsies: Genotyping circulating tumor DNA[J]. J Clin Oncol, 2014, 32(6):579-586.
4	Yoon KA, Park S, Lee SH, et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls[J]. J Mol Diagn, 2009, 11(3):182-185.
5	Heitzer E, Auer M, Hoffmann EM, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer[J]. Int J Cancer, 2013, 133(2):346-356.
6	Nakao M, Muramatsu H, Sone K, et al. Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: a retrospective analysis[J]. Mol Clin Oncol, 2015, 3(2):403-407.
7	Shao ZM, Nguyen M. Tumor-specific DNA in plasma of breast cancer patients[J]. Anti-cancer Drngs, 2002, 13(4):353-357.
8	Lee HS, Hwang SM, Kim TS, et al. Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon[J]. Transl Oncol, 2013, 6(3):290-296.
9	Wu Y, Du X, Xue C, et al. Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer[J]. Med Oncol, 2013, 30(4):737.
10	Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J]. Nat Med, 2014, 20(5):552-558.
11	Ulivi P, Mercatali L, Casoni GL, et al. Multiple marker detection in peripheral blood for NSCLC diagnosis[J]. PLoS One, 2013, 8(2):e57401.
12	Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types[J]. Mol Oncol, 2015, 9(4):783-790.
13	Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease[J]. Br J Cancer, 2015, 113(3):476-483.
14	邓水秋，欧阳学农，余宗阳，等. 晚期非小细胞肺癌血清游离DNA水平变化及意义[J]. 山东医药，2013, 53(30):6-8.
15	Madhavan D, Wallwiener M, Bents, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis[J]. Breast Cancer Res Treat, 2014, 146(1):163-174.
16	Perrone F, Lampis A, Bertan C, et al. Circulating free DNA in a screening program for early colorectal cancerdetection[J]. Tumori, 2014, 100(2):115-121.
17	Battaglia P, Baritono E, Remo A, et al. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer[J]. Tumori, 2014, 100(2):122-127.
18	Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial[J]. Lancet Oncol, 2015, 16(8):937-948.
19	Spindler KL, Pallisgaard N, Andersen RF, et al. Changes in mutational status during third-line treatment for metastatic colorectal cancer-results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma[J]. Int J Cancer, 2014, 135(9):2215-2222.
20	Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial[J]. Lancet Oncol, 2015，16(8):937-948.

临床资料		例数	游离DNA水平	t值	P值
性别		?	?	1.9845	0.7602
?	男	64	198.38±80.98	?	?
?	女	52	203.56±97.78	?	?
年龄/岁		?	?	?	?
?	≤60	49	194.32±87.52	1.9830	0.5076
?	>60	67	205.37±89.64	?	?
吸烟		?	?	?	?
?	有	68	206.06±93.10	1.9822	0.4303
?	无	48	193.11±82.01	?	?
病理类型		?	?	?	?
?	腺癌	60	207.90±80.58	1.9824	0.3698
?	鳞癌	56	192.98±96.48	?	?
临床分期		?	?	?	?
?	Ⅰ/Ⅱ期	50	172.75±72.87	1.9812	0.0019
?	Ⅲ/Ⅳ期	66	221.88±93.86	?	?

临床资料		例数	游离DNA水平	t值	P值
性别		?	?	1.9845	0.7602
?	男	64	198.38±80.98	?	?
?	女	52	203.56±97.78	?	?
年龄/岁		?	?	?	?
?	≤60	49	194.32±87.52	1.9830	0.5076
?	>60	67	205.37±89.64	?	?
吸烟		?	?	?	?
?	有	68	206.06±93.10	1.9822	0.4303
?	无	48	193.11±82.01	?	?
病理类型		?	?	?	?
?	腺癌	60	207.90±80.58	1.9824	0.3698
?	鳞癌	56	192.98±96.48	?	?
临床分期		?	?	?	?
?	Ⅰ/Ⅱ期	50	172.75±72.87	1.9812	0.0019
?	Ⅲ/Ⅳ期	66	221.88±93.86	?	?

[1]	Zhidong Zhao, Zhongli Li. Research progress of early diagnosis and treatment in osteoarthritis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 689-693.
[2]	Yu He, Yujuan Wang, Rong Gao, Han Li, Changying Hu, Junling Yang. Clinical value of a new biomarker serum soluble myeloid cell triggered receptor-1 in early diagnosis of severe pneumonia [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(05): 307-312.
[3]	Jia Yan, Shuangchi Liu, Zhengyu Wang. Progress in the research and application of tumor markers for gallbladder cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 391-394.
[4]	Xiaoman Chen, Haibo Zhang, Manjie Xue, Bo Wei, Jun Shao, Xiaoyan Han. Impact of -80℃ cryopreservation on miRNA markers in colorectal cancer plasma sample [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(01): 24-27.
[5]	Zhiming Li, Chenming Guo, Xiaochen Zhuang, Xueqin Hou, Junxi Gao. Comparative study of qualitative and quantitative indicators of contrast-enhanced ultrasound in early breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 639-643.
[6]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[7]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[8]	Yuan Wang, Yi Yang, Yunfei Mou, Fuqiang Ren, Xin Huang. Analysis of postoperative osimertinib targeted therapy in patients with resectable non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(05): 657-660.
[9]	Xinxiong Li, Zaizhong Zhang, Hu Zhao, Chunhong Xiao, Lie Wang. Progress of exosome contents as diagnostic markers for pancreatic cancer [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(01): 53-57.
[10]	Chengming Ding, Jiafeng Hou, Guangwei Tao. Early diagnosis and screening of hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(01): 22-28.
[11]	Ruiqi Gu, Hongsheng Fang, Guoxiang Cai. Application and progress of circulating tumor DNA detection technology in the diagnosis and treatment of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 453-459.
[12]	Taotao Ren, Xi Qiao. Progress of research on early biomarkers of acute kidney injury [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(01): 32-38.
[13]	Jing Mo, Guowei Chen, Shiyu Zhang. Effect of intraperitoneal hyperthermic perfusion chemotherapy at different times after operation on tumor marker levels in patients with ovarian cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(02): 165-170.
[14]	Leilei Shen, Yang Liu. The staging evolution and treatment strategies of stage ⅠB non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(04): 246-254.
[15]	Qiang Wang, Huan Zhang, Jun Pan. Significance of tumor markers in the differential diagnosis of pleural effusion in elderly patients [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2022, 09(04): 16-21.

Please choose a citation manager

Content to export